Every Avenbuan engagement is sourced to primary documents, framed for boardroom decision-making, and refreshable as new data lands. Fixed fees, fixed timelines, McKinsey-grade output.
McKinsey-grade competitive intelligence on a therapeutic area, asset cohort, or specific franchise — written for the C-suite and the investment committee.
Independent commercial and clinical evaluation of in-licensing, M&A, and partnership targets. Designed to clear an investment-committee vote without needing rework.
Phase 1 through Phase 3 monitoring across a defined therapeutic area, with AI-assisted clinical-trial database integration and decision-relevant alerts.
EU/UK/US payer, regulatory, and HTA scenario design for novel-mechanism assets. We map the policy and reimbursement terrain before launch economics are locked.
Single-thread strategic memos prepared for principals. Decision-grade language, two-page format, source index attached.
Custom analytic engagements for corporate-development, BD&L, investor-relations, and competitive-intelligence teams. Scoped, fixed-fee, two-week sprints.
A predictable five-step process. No bait-and-switch on scope, no surprise change orders, no AI-generated figures that crumble under board scrutiny.
We agree the question, the audience, the deliverable format, and the timeline. You receive a scoping memo within 24 hours.
Scope, timeline, fee, deliverables, and refresh terms — all in one page. No hourly billing surprises.
Source-extraction, data triangulation, draft assembly. Mid-sprint check-in with the named analyst.
Every quantitative claim passes a four-stage verification: primary-source trace, figure check, date & context confirmation, inclusion-criteria review.
You receive the deliverable plus a 30-minute live Q&A with the analyst. Source index is permanent — every figure remains traceable.
Tell us the question; we’ll recommend the right shape of engagement and pricing — usually within one working day.